65,437 trials
Rhinitis, Allergic, Perennial
Primary: Number of Participants With Adverse Events and Adverse Drug Reactions — 76; 18 participants
Hypertension
Primary: Mean Difference of Systolic Daytime Ambulatory Blood Pressure Between Summer and Winter. — 7.7 mmHg
Chronic Lymphocytic Leukemia
Primary: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC) — 660; 813 Days — p=0.0218
Osteoarthritis · Pain · Morning Stiffness
Primary: Day and Night Mean Pain Score for the Previous 24 Hours on a Nine-point Scale (0 = no Pain to 8 = Very Severe Pain) at Visit 3 (4 Weeks Following Treatment) in…
Influenza
Primary: Seroconversion — 29; 32; 37; 35 Number of subjects
Insomnia
Primary: Number of Participants Whose Standard Deviation of Lateral Position (SDLP) Following Active Treatment As Compared to Placebo In Relation To The 2.5 cm SDLP Threshold…
Sleep Apnea, Obstructive
Primary: Obstructive Sleep Apnea — 41 participants — p=<0.0001
Insomnia
Primary: Latency to Persistent Sleep After Middle-of-the-Night Awakening as Measured by Polysomnography — 9.69; 16.89; 28.12 minutes — p=<0.001
Type 2 Diabetes Mellitus (T2DM)
Primary: Proportion of Participants With at Least One Symptomatic Hypoglycemic Event — 0.07; 0.13 proportion of participants — p=0.0005
Insomnia
Primary: Latency to Sleep Onset After Middle-of-the-Night Awakening at Baseline — 68.13; 69.42 minutes
Open-angle Glaucoma · Ocular Hypertension
Primary: The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4 — 25.20; 24.87; -9.38; -8.93 Millimeters of…
Facial Wrinkles
Primary: Adjusted (LS) Mean Change From Baseline in Wrinkle Severity Rating Scale (SRS) Score of Each Nasolabial Fold (NLF) as Determined by the Blinded Evaluator at Week 12…
HIV Infections
Primary: Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population — 384; 409; 122; 96…
Interstitial Cystitis
Primary: Number Subjects at Least "Moderately Improved" for Each Treatment Group in Patient Reported Global Response Assessment (GRA) — 31; 26; 30 participants
Acne Vulgaris
Primary: Number of Participants Who Were a Success (Subject's Global Assessment of 'Clear' or 'Almost Clear') at Week 12 — 18 participants